(Q45929234)

17 December 2017

title

Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study. (English)

1 reference

17 December 2017

1 reference

Heidi T May

2

0 references

author name string

Jeffrey L Anderson

1

1 reference

17 December 2017

Tami L Bair

3

1 reference

17 December 2017

Joseph B Muhlestein

4

1 reference

17 December 2017

Benjamin D Horne

5

1 reference

17 December 2017

John F Carlquist

6

1 reference

17 December 2017

publication date

14 July 2009

1 reference

17 December 2017

Journal of Cardiovascular Pharmacology and Therapeutics

published in

1 reference

17 December 2017

volume

14

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

page(s)

170-175

1 reference

17 December 2017

Management of the irritable bowel syndrome

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1074248409340158

Review article: irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409340158

Review article: tegaserod

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409340158

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409340158

5-hydroxytryptamine receptors in the human cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409340158

Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409340158

Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409340158

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409340158

A systematic review of tegaserod for the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409340158

Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409340158

Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409340158

Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409340158

Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409340158

A coronary heart disease risk score based on patient-reported information

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409340158

The FDA's decision-making process: isn't it time to temper the principle of protective paternalism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409340158

21 January 2018

Identifiers

DOI

10.1177/1074248409340158

1 reference

17 December 2017

1 reference

17 December 2017